Vericiguat: The Fifth Harmony of Heart Failure with Reduced Ejection Fraction.

ABSTRACT: Heart failure with reduced ejection fraction is a chronic and progressive syndrome that continues to be a substantial financial burden for health systems in Western countries. Despite remarkable advances in pharmacologic and device-based therapy over the last few years, patients with heart failure with reduced ejection fraction have a high residual risk of adverse outcomes, even when treated with optimal guideline-directed medical therapy and in a clinically stable state. Worsening heart failure episodes represent a critical event in the heart failure trajectory, carrying high residual risk at discharge and dismal short- or long-term prognosis. Recently, vericiguat, a soluble guanylate cyclase stimulator, has been proposed as a novel drug whose use is already associated with a reduction in

SUBMITTER: Falco L 

PROVIDER: S-EPMC10531735 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature